The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
Abstract
Summary: The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema is proposed for inhibitor surveillance, which varies according to the severity of the haemophilia and the treatment type and regimen used. The methodological and pharmacokinetic approach to inhibitor surveillance in congenital haemophilia has been updated. Factor VIII/IX genotyping of patients is recommended to identify those at increased risk. All patients who develop an inhibitor should be considered for immune tolerance induction (ITI). The decision to attempt ITI for FIX inhibitors must be carefully weighed against the relatively high risk of reactions and the nephrotic syndrome and the relatively low response rate observed in this group. The start of ITI should be deferred until the inhibitor has declined below 10 Bethesda Units/ml, where possible. ITI should continue, even in resistant patients, where it is well tolerated and so long as there is a convincing downward trend in the inhibitor titre. The choice of treatment for bleeding in inhibitor patients is dictated by the severity of the bleed, the current inhibitor titre, the previous anamnestic response to FVIII/IX, the previous clinical response and the side‐effect profile of the agents available. We have reviewed novel dose‐regimens and modes of administration of FEIBA (factor VIII inhibitor bypassing activity) and recombinant activated FVII (rVIIa) and the extent to which these agents may be used for prophylaxis and surgery. Bleeding in acquired haemophilia is usually treated with FEIBA or rVIIa. Immunosuppressive therapy should be initiated at the time of diagnosis with Prednisolone 1 mg/kg/d ± cyclophosphamide. In the absence of a response to these agents within 6 weeks, second‐line therapy with Rituximab, Ciclosporin A, or other multiple‐modality regimens may be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII
Green, D., & Lechner, K. (1981) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650169 · Cited by 773
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
Delgado, J., Jimenez‐Yuste, V., Hernandez‐Navarro, F., & Villar, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04162.x · Cited by 469
Gilchrist, G., Hoots, W. K., Cooper, H., Gastineau, D., & Shapiro, A. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615357 · Cited by 368
Aledort, L., Beardsley, D., Cooper, H., Davignon, G., Ewenstein, B., Gilchrist, G., Gill, J., Glader, B., Hoots, W. K., Kisker, C. T., et al. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615388 · Cited by 354
Gl, B., Gomperts, E. D., Courter, S. G., Gruppo, R. A., Em, G., Manco‐Johnson, M. J., Shapiro, A. D., Scheibel, E., White, G. C., & Lee, M. (1994) · PubMed · doi:10.1182/blood.v83.9.2428.bloodjournal8392428 · Cited by 346
The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study
Hay, C. R. M., Negrier, C., & Ludlam, C. A. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1665434 · Cited by 344
Self-citationAbshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Sjamsoedin, L. J. M., Heijnen, L., Mauser-Bunschoten, E. P., van Geijlswijk, J. L., van Houwelingen, H., van Asten, P., & Sixma, J. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109243051301 · Cited by 304
Aledort, L. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00944.x · Cited by 286
Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P., & the members of the French FEIBA study group (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656122 · Cited by 276
Use of porcine factor VIII in the treatment of patients with acquired hemophilia
Morrison, A., Ludlam, C., & Kessler, C. (1993) · Blood · doi:10.1182/blood.v81.6.1513.1513 · Cited by 254
Lusher, J. M., Shapiro, S. S., Palascak, J. E., Rao, A. V., Levine, P. H., Blatt, P. M., & the Hemophilia Study Group (1980) · New England Journal of Medicine · doi:10.1056/nejm198008213030803 · Cited by 246
Green, D., Rademaker, A. W., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649664 · Cited by 236
Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’
Brackmann, H. H., Oldenburg, J., & Schwaab, R. (1996) · Vox Sanguinis · doi:10.1111/j.1423-0410.1996.tb01346.x · Cited by 221
EHRLICH, H. J., HENZL, M. J., & GOMPERTS, E. D. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00532.x · Cited by 220
Clinical experience with recombinant factor VIIa
Lusher, J., Ingerslev, J., Roberts, H., & Hedner, U. (1998) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199803000-00002 · Cited by 215
Lusher, Roberts, Davignon, Joist, Smith, Shapiro, Laurian, Kasper, Mannucci, & rFVIIa Study Group (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.00209.x · Cited by 212
Astermark, J., Berntorp, E., White, G. C., Kroner, B. L., & THE MIBS STUDY GROUP (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00510.x · Cited by 207
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia
Stasi, R., Brunetti, M., Stipa, E., & Amadori, S. (2004) · Blood · doi:10.1182/blood-2003-11-4075 · Cited by 198
White, G. C., Beebe, A., & Nielsen, B. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657536 · Cited by 192
Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A
Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R., Peake, I. R., Berntorp, E., Bunschoten, E. P. M., Fijnvandraat, K., et al. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615061 · Cited by 187
Self-citationHay, C. R. M., Ludlam, C. A., Colvin, B. T., Hill, F. G. H., Preston, F. E., Wasseem, N., Bagnall, R. D., Peake, I. R., Berntorp, E. E., Mauser‐Bunschoten, E. P., et al. (1998) · PubMed · Cited by 186
Self-citationLUSHER, J. M., ARKIN, S., ABILGAARD, C. F., & SCHWARTZ, R. S. (1993) · Survey of Anesthesiology · doi:10.1097/00132586-199310000-00058 · Cited by 181
Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L., & for the ReFacto Phase 3 Study Group (2003) · Haemophilia · doi:10.1046/j.1365-2516.2003.00708.x · Cited by 177
Turecek, P. L., Váradi, K., Gritsch, H., & Schwarz, H. P. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00934.x · Cited by 172
McMillan, C., Shapiro, S., Whitehurst, D., Hoyer, L., Rao, A., & Lazerson, J. (1988) · Blood · doi:10.1182/blood.v71.2.344.344 · Cited by 169
Lottenberg, R. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370060073014 · Cited by 167
Schwartz, R., Gabriel, D., Aledort, L., Green, D., & Kessler, C. (1995) · Blood · doi:10.1182/blood.v86.2.797.bloodjournal862797 · Cited by 167
Laffan, M., Brown, S. A., Collins, P. W., Cumming, A. M., Hill, F. G. H., Keeling, D., Peake, I. R., & Pasi, K. J. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00894.x · Cited by 164
Self-citationTreatment of acquired haemophilia with factor eight inhibitor bypassing activity
Sallah, S. (2004) · Haemophilia · doi:10.1046/j.1365-2516.2003.00856.x · Cited by 163
Pharmacokinetics of Coagulation Factors: Clinical Relevance for Patients with Haemophilia
Bj??rkman, S., & Berntorp, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00003 · Cited by 159
A population based, unselected, consecutive cohort of patients with acquired haemophilia A
Collins, P., Macartney, N., Davies, R., Lees, S., Giddings, J., & Majer, R. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04731.x · Cited by 159
Self-citationHauser, I. J., Schneider, B., & Lechner, K. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651666 · Cited by 149
Hay, C. R. M., Baglin, T. P., Collins, P., Hill, F. G. H., & Keeling, D. M. (2000) · British Journal of Haematology · doi:10.1111/j.1365-2141.2000.02327.x · Cited by 142
Self-citationTarantino, M. D., Collins, P. W., Hay, C. R. M., Shapiro, A. D., Gruppo, R. A., Berntorp, E. E., Bray, G. L., Tonetta, S. A., Schroth, P., Retzios, A. D., et al. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00932.x · Cited by 141
Self-citationPasi, J., Collins, P. W., Keeling, D. M., Brown, S. A., Cumming, A. M., Dolan, G., Hay, C. R. M., Hill, F. G. H., Laffan, M., & Peake, I. R. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00886.x · Cited by 138
Self-citationHauser, I. J., Schneider, B., & Lechner, K. (1995) · PubMed · Cited by 135
Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France
Sultan, Y., & French Hemophilia Study Group (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648507 · Cited by 135
Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B
Ewenstein, B. M., Takemoto, C., Warrier, I. A., Lusher, J. M., Saidi, P., Eisele, J., Ettinger, L. J., & DiMichele, D. (1997) · Blood · doi:10.1182/blood.v89.3.1115 · Cited by 130
Santagostino, E., Gringeri, A., & Mannucci, P. M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01128.x · Cited by 128
Combination Immunosuppressive Therapy after Factor VIII Infusion for Acquired Factor VIII Inhibitor
Lian, E., Larcada, A. F., & Chiu, A. Y.-Z. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-10-774 · Cited by 122
Zeitler, H., Ulrich-Merzenich, G. S., Heß, L., Konsek, E., Unkrig, C., Walger, P., Vetter, H., & Brackmann, H. (2004) · Blood · doi:10.1182/blood-2004-05-1811 · Cited by 120
Clinical evaluation of recombinant factor IX.
White, G., Shapiro, A. D., Ragni, M. V., Garzone, P. D., Goodfellow, J., Tubridy, K. L., & Courter, S. G. (1998) · PubMed · Cited by 105
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience
Carcao, M. D., Louis, J. S., Poon, M., Grunebaum, E., LACROIX, S., Stain, A. M., Blanchette, V. S., & Rivard, G. (2005) · Haemophilia · doi:10.1111/j.1365-2516.2005.01170.x · Cited by 101
Ewenstein, B. M., Joist, J. H., Shapiro, A. D., Hofstra, T. C., Leissinger, C., Seremetis, S. V., Broder, M., Mueller‐Velten, G., Schwartz, B. A., & Mononine Comparison Study Group (2002) · Transfusion · doi:10.1046/j.1537-2995.2002.00039.x · Cited by 100
van Geijlswijk, J. L. (1982) · Springer eBooks · doi:10.1007/978-94-011-9764-9_8 · Cited by 86
Coller, B., Hultin, M., Hoyer, L., Miller, F. W., Dobbs, J., Dosik, M., & Berger, E. R. (1981) · Blood · doi:10.1182/blood.v58.3.619.619 · Cited by 85
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors
Young, G. A., McDaniel, M., & Nugent, D. J. (2005) · Haemophilia · doi:10.1111/j.1365-2516.2005.01096.x · Cited by 79
DDAVP in acquired hemophilia a: Case report and review of the literature
Mudad, R., & Kane, W. H. (1993) · American Journal of Hematology · doi:10.1002/ajh.2830430413 · Cited by 75
Morfini, M., Cinotti, S., Bellatreccia, A., Paladino, E., Gringeri, A., & Mannucci, P. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00481.x · Cited by 58
Schulman, S., Langevitz, P., Livneh, A., Martinowitz, U. P., Seligsohn, U., & Varon, D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650581 · Cited by 54
Dosing with recombinant factor viia based on current evidence
Hedner, U. K. E. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2003.11.008 · Cited by 50
Freedman, J. J., Rand, M. L., Russell, O., Davis, C., Cheatley, P. L., Blanchette, V. S., & Garvey, M. B. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00559.x · Cited by 44
Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors
Batlle, J., López, Brackmann, Gaillard, Goudemand, Humbert, Moerloose, D., Maass, Mauz‐Körholz, Sultan, et al. (1999) · Haemophilia · doi:10.1046/j.1365-2516.1999.00354.x · Cited by 38
Genetics and molecular biology of haemophilias A and B
Green, P. M., Montandon, A. J., Bentley, D. R., & Giannelli, F. (1991) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199108000-00007 · Cited by 36
Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor
Pfliegler, G., Boda, Z., Hársfalvi, J., Flóra-Nagy, M., Sari, B. M. M., Pecze, K., & Rák, K. (1989) · Postgraduate Medical Journal · doi:10.1136/pgmj.65.764.400 · Cited by 36
In VitroDetection of Mild Inhibitors to Factor VIII in Hemophilia
Ewing, N. P., & Kasper, C. K. (1982) · American Journal of Clinical Pathology · doi:10.1093/ajcp/77.6.749 · Cited by 35
Aquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone
Lian, E., Villar, M. J., Noy, L. I., & Dayao, Z. R. (2002) · American Journal of Hematology · doi:10.1002/ajh.10070 · Cited by 35
Inhibitors to Factor VIII/IX: Treatment of Inhibitors—Immune Tolerance Induction
Hay, C. R. M. (2005) · Wiley eBooks · doi:10.1002/9780470987124.ch13 · Cited by 12
Self-citation
Cited by
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
Collins, P. W., Hirsch, S., Baglin, T. P., Dolan, G., Hanley, J., Makris, M., Keeling, D. M., Liesner, R., Brown, S. A., Hay, C. R. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-029850 · Cited by 749
Self-citationRevisions to the Canadian Emergency Department Triage and Acuity Scale (CTAS) Guidelines 2016
Bullard, M. J., Musgrave, E., Warren, D., Unger, B., Skeldon, T., Grierson, R., van der Linde, E., & Swain, J. (2017) · CJEM · doi:10.1017/cem.2017.365 · Cited by 495
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Hay, C. R. M., & DiMichele, D. M. (2012) · Blood · doi:10.1182/blood-2011-08-369132 · Cited by 449
Self-citationInternational recommendations on the diagnosis and treatment of patients with acquired hemophilia A
Huth-Kuhne, A., Baudo, F., Collins, P., Ingerslev, J., Kessler, C. M., Levesque, H., Castellano, M. E. M., Shima, M., & St-Louis, J. (2009) · Haematologica · doi:10.3324/haematol.2008.001743 · Cited by 433
Self-citation
Metadata
- Authors
- Hay, C. R. M., Brown, S., Collins, P. W., Keeling, D. M., & Liesner, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2006-05-16
- Volume
- 133
- Issue
- 6
- Pages
- 591-605
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2108177522
- Cited by
- 327
- References
- 60
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.